BG63146B1 - Капсули с контролирано освобождаване на активнитевещества - Google Patents

Капсули с контролирано освобождаване на активнитевещества Download PDF

Info

Publication number
BG63146B1
BG63146B1 BG100596A BG10059696A BG63146B1 BG 63146 B1 BG63146 B1 BG 63146B1 BG 100596 A BG100596 A BG 100596A BG 10059696 A BG10059696 A BG 10059696A BG 63146 B1 BG63146 B1 BG 63146B1
Authority
BG
Bulgaria
Prior art keywords
synthetic membrane
agents
biologically active
membrane capsules
active substance
Prior art date
Application number
BG100596A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100596A (bg
Inventor
Mantripragada Sankaram
Sinil Kim
Original Assignee
Depotech Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22548158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63146(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Depotech Corporation filed Critical Depotech Corporation
Publication of BG100596A publication Critical patent/BG100596A/bg
Publication of BG63146B1 publication Critical patent/BG63146B1/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/08Systemic pesticides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
BG100596A 1993-11-16 1996-05-16 Капсули с контролирано освобождаване на активнитевещества BG63146B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15365793A 1993-11-16 1993-11-16
PCT/US1994/012957 WO1995013796A1 (en) 1993-11-16 1994-11-10 Vesicles with controlled release of actives

Publications (2)

Publication Number Publication Date
BG100596A BG100596A (bg) 1996-12-31
BG63146B1 true BG63146B1 (bg) 2001-05-31

Family

ID=22548158

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100596A BG63146B1 (bg) 1993-11-16 1996-05-16 Капсули с контролирано освобождаване на активнитевещества

Country Status (25)

Country Link
US (1) US6132766A (de)
EP (1) EP0729351B1 (de)
JP (1) JP3002702B2 (de)
KR (1) KR100241300B1 (de)
CN (1) CN1099868C (de)
AT (1) ATE196248T1 (de)
AU (1) AU686277B2 (de)
BG (1) BG63146B1 (de)
BR (1) BR9408072A (de)
CA (1) CA2176712C (de)
DE (1) DE69425901T2 (de)
DK (1) DK0729351T3 (de)
ES (1) ES2149955T3 (de)
FI (1) FI115823B (de)
GR (1) GR3034954T3 (de)
HU (1) HUT75162A (de)
IL (1) IL111628A (de)
NO (1) NO304577B1 (de)
NZ (1) NZ276305A (de)
PL (1) PL314485A1 (de)
PT (1) PT729351E (de)
RO (1) RO116341B1 (de)
RU (1) RU2160093C2 (de)
WO (1) WO1995013796A1 (de)
ZA (1) ZA949063B (de)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
DE69717661T2 (de) * 1996-09-13 2003-09-25 Lipoxen Technologies Ltd Liposomenzusammensetzung
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
CN1241902A (zh) * 1996-10-25 2000-01-19 孟山都公司 用外源化学物质处理植物的组合物和方法
JP4155601B2 (ja) * 1996-10-25 2008-09-24 モンサント・テクノロジー・エルエルシー 外因性化学物質で植物を処理するための組成物および方法
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP0948538B1 (de) 1996-12-13 2008-06-11 Novartis Vaccines and Diagnostics, Inc. Analyse und separation von pdgf-proteinen
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
JP4467789B2 (ja) * 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド 持続放出性リポソーム麻酔組成物
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
CA2309548A1 (en) 1997-11-14 1999-05-27 Skyepharma Inc. Production of multivesicular liposomes
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
NZ541361A (en) 1998-05-01 2008-04-30 Inst Genomic Research Neisseria meningitidis antigens and compositions relating to SEQ ID Nos:2916, 2918 and 2920
EP1953229A3 (de) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatische Brust- und Dickdarmkrebs-regulierte Gene
DK1141331T3 (da) 1998-12-16 2009-01-05 Novartis Vaccines & Diagnostic Human cyclinafhængig kinase (hPNQALRE)
AU781703B2 (en) * 1999-01-25 2005-06-09 Blue Ridge Pharmaceuticals, Inc. Liposome formulations
MXPA01010924A (es) 1999-04-30 2002-05-06 Chiron Spa Antigenos de neisseria conservados.
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
WO2001000654A2 (en) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2275553B1 (de) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Antigenpeptide aus Neisseria
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
CA2395314A1 (en) 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
ES2507100T3 (es) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
BR0108711A (pt) 2000-02-28 2004-06-22 Chiron Spa Expressão heteróloga de proteìnas de neisseria
EP1261638A2 (de) 2000-03-08 2002-12-04 Chiron Corporation Humanes fgf-23 gen und genexpressionsprodukte
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1953243B1 (de) 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Polynukleotide im Zusammenhang mit Darmkrebs
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
JP2004535765A (ja) 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
KR20030022094A (ko) 2001-05-24 2003-03-15 (주)휴먼디엔에이테크놀로지 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
CN100398551C (zh) 2001-11-09 2008-07-02 乔治敦大学 新的血管内皮细胞生长抑制剂同种型
KR100982204B1 (ko) 2001-12-12 2010-09-14 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 클라미디아 트라코마티스에 대한 면역화
ES2323456T3 (es) 2002-01-08 2009-07-16 Novartis Vaccines And Diagnostics, Inc. Productos genicos diferencialmente expresados en celulas de pecho cancerosas y sus metodos de uso.
EP1572933A4 (de) 2002-02-13 2007-09-05 Univ Duke Modulation der immunantwort durch polypeptide als antwort auf nichtpeptidischen bindungsstress
FR2836043B1 (fr) * 2002-02-15 2004-06-04 Inst Nat Sante Rech Med Vesicules lipidiques, preparation et utilisations
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
WO2003080808A2 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
CA2489919A1 (en) * 2002-07-03 2004-01-15 Aphton Corporation Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CA2516138A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1594441B1 (de) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2536393A1 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample
BRPI0417270A (pt) 2003-12-23 2007-03-27 Rinat Neuroscience Corp anticorpos agonistas antitrkc e métodos para utilização dos mesmos
AU2005204378B2 (en) * 2004-01-12 2009-01-22 Mannkind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
DK1736541T3 (da) 2004-03-29 2013-05-06 Galpharma Co Ltd Nyt modificeret galectin 9-protein og anvendelse heraf
US7223562B2 (en) 2004-03-31 2007-05-29 New York University Compositions for controlling hair growth
KR20060135060A (ko) 2004-04-07 2006-12-28 리나트 뉴로사이언스 코퍼레이션 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
ES2309766T3 (es) * 2004-06-04 2008-12-16 Camurus Ab Formulaciones liquidas de liberacion lenta.
AU2005327194B2 (en) 2004-07-09 2010-09-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus G glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP2298807A3 (de) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Gegen das Amyloid-beta-Peptid gerichtete Antikörper und Verfahren zu deren Anwendung
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
JP4990142B2 (ja) 2004-08-23 2012-08-01 マンカインド コーポレイション 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
DE05852057T1 (de) 2004-11-23 2007-11-29 Neuromolecular Pharmaceuticals Inc., Emeryville Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
EP1858919B1 (de) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immungene von uropathogenen escherichia coli
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
WO2006110599A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cacna1e in cancer diagnosis, detection and treatment
JP2008535853A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗cd26抗体およびその使用方法
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
SI2380592T1 (en) 2005-11-14 2018-06-29 Teva Pharmaceuticals International Gmbh The antibody to the calcitonin-related peptide antagonist
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
AU2007216966C1 (en) 2006-02-22 2014-03-20 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
SG172684A1 (en) 2006-06-07 2011-07-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2035035A2 (de) 2006-06-09 2009-03-18 Novartis AG Immunogene zusammensetzungen für streptococcus agalactiae
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
EP2134365B1 (de) 2007-03-21 2019-03-13 Effat Emamian Zusammensetzung und verfahren zur hemmung von zellwachstum
WO2008124176A2 (en) 2007-04-10 2008-10-16 The Administrators Of The Tulane Educational Fund Soluble and membrane-anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
WO2009077993A2 (en) 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
ES2550757T3 (es) 2007-12-18 2015-11-12 Bioalliance C.V. Anticuerpos que reconocen un epítopo que contiene carbohidratos en CD43 y ACE expresados en células cancerosas y métodos de uso de los mismos
JP2011516078A (ja) 2008-04-10 2011-05-26 セル・シグナリング・テクノロジー・インコーポレイテツド 癌におけるegfr突然変異を検出する組成物および方法
CN102112110A (zh) * 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
ES2655921T3 (es) 2008-06-13 2018-02-22 Mannkind Corporation Un inhalador de polvo seco y sistema para administración de fármacos
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2904623T3 (es) 2008-06-20 2022-04-05 Mannkind Corp Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
AU2009302042A1 (en) * 2008-10-07 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
ES2733084T3 (es) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Antígenos de Chlamydia
EP2405963B1 (de) 2009-03-11 2013-11-06 MannKind Corporation Gerät, system und verfahren zur messung von widerstand in einem inhaliergerät
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
TWI596114B (zh) 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-il-7受體抗體及方法
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
MX2012010481A (es) 2010-03-11 2012-10-09 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente del ph.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
KR20130117755A (ko) 2010-06-21 2013-10-28 맨카인드 코포레이션 건조 분말 약물 운반 시스템 및 방법
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
JP6194248B2 (ja) * 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2630953B1 (de) * 2010-12-27 2017-08-09 Terumo Kabushiki Kaisha Liposomzusammensetzung und herstellungsverfahren dafür
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
RU2480479C1 (ru) * 2011-11-01 2013-04-27 Елена Викторовна Свирщевская Гетерологичный пептидный мини-антиген в составе полимерной частицы для создания противоаллергенной вакцины
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CN104169301A (zh) 2011-12-22 2014-11-26 瑞纳神经科学公司 人生长激素受体拮抗剂抗体及其使用方法
WO2013168167A1 (en) 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
FR2991196B1 (fr) * 2012-05-29 2014-06-27 Capsum Nanoparticules ciblantes pour une application biologique
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
US20150191702A1 (en) 2012-07-02 2015-07-09 Commonwealth Scientific And Industrial Research Organization Paramyxovirus and Methods of Use
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
EP2877155B1 (de) 2012-07-26 2020-10-28 Camurus AB Opioid-formulierungen
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
BR112015010722A2 (pt) 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
RU2018137673A (ru) 2012-11-30 2019-03-22 Глаксосмитклайн Байолоджикалс Са Антигены и комбинации антигенов pseudomonas
KR20160029731A (ko) 2013-03-12 2016-03-15 더 제너럴 하스피탈 코포레이션 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도
CN105051051B (zh) 2013-03-15 2021-07-16 萨瑞斯治疗控股公司 用于合成神经鞘磷脂和二氢神经鞘磷脂的方法
JP6499155B2 (ja) 2013-03-15 2019-04-10 ロマ リンダ ユニバーシティ 自己免疫疾患の治療
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US20160017055A1 (en) 2013-03-15 2016-01-21 Dyax Corp. Anti-plasma kallikrein antibodies
CN105189560A (zh) 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3021834A1 (de) 2013-07-18 2016-05-25 MannKind Corporation Hitzestabile pharmazeutische trockenpulverzusammensetzungen und verfahren
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
TWI623551B (zh) 2013-08-02 2018-05-11 輝瑞大藥廠 抗cxcr4抗體及抗體-藥物結合物
EP3030294B1 (de) 2013-08-05 2020-10-07 MannKind Corporation Insufflationsvorrichtung
SG10201810298VA (en) 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
JP2017504589A (ja) 2013-12-11 2017-02-09 ザ ジェネラル ホスピタル コーポレイション 避妊および卵巣予備能の保存のためのミュラー管抑制物質(mis)タンパク質の使用
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
PE20220337A1 (es) 2014-03-21 2022-03-14 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
EP3785700A1 (de) 2014-04-21 2021-03-03 Heron Therapeutics, Inc. Zusammensetzungen aus einem polyorthoester und einem organischen sauren trägerstoff
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
PL3134068T3 (pl) 2014-04-21 2021-12-20 Heron Therapeutics, Inc. Polimerowe układy do dostarczania leków o przedłużonym uwalnianiu
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
EP3139955B1 (de) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusionsproteine zur behandlung von krebs und zugehörige verfahren
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
GB2541835B (en) * 2015-01-21 2018-09-12 Pacira Pharmaceuticals Inc Multivesicular liposome formulations of tranexamic acid
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
TWI787645B (zh) 2015-04-13 2022-12-21 美商輝瑞股份有限公司 Cd3特異性抗體、治療性雙特異性抗體及其用途
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
MX2018000714A (es) 2015-07-21 2019-11-18 Dyax Corp Un inhibidor de anticuerpo monoclonal de factor xiia.
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
KR20230074843A (ko) 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
IL305148A (en) 2015-09-15 2023-10-01 Scholar Rock Inc Anti-pro/hidden myostatin antibodies and their uses
US10138298B2 (en) 2015-10-23 2018-11-27 The Regents Of The University Of California Anti-IL-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 抗pd-1抗体及其治疗用途
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017125831A1 (en) 2016-01-21 2017-07-27 Pfizer Inc. Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
EP3541815A4 (de) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. Multivesikuläre liposomenformulierung mit zinkmeloxicamkomplex-mikropartikeln und verfahren zur herstellung davon
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
KR20190124753A (ko) 2017-03-03 2019-11-05 리나트 뉴로사이언스 코프. 항-gitr 항체 및 이의 사용 방법
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
PE20191846A1 (es) 2017-06-02 2019-12-31 Pfizer Anticuerpos especificos para flt3 y sus usos
WO2018231771A1 (en) 2017-06-13 2018-12-20 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
EP3651799A1 (de) 2017-07-13 2020-05-20 Massachusetts Institute of Technology Targeting des hdac2-sp3-komplexes zur verbesserung der synaptischen funktion
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
WO2019070161A2 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc ARTICLES AND METHODS FOR PERSONALIZED THERAPY OF CANCER
AU2019215075A1 (en) 2018-02-01 2020-08-20 Pfizer Inc. Antibodies specific for CD70 and their uses
KR20200128018A (ko) 2018-02-01 2020-11-11 화이자 인코포레이티드 Cd70을 표적으로 하는 키메라 항원 수용체
JP2021516045A (ja) 2018-02-28 2021-07-01 ファイザー・インク Il−15バリアントおよびその使用
TWI816396B (zh) 2018-05-23 2023-09-21 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
TWI793325B (zh) 2018-05-23 2023-02-21 美商輝瑞大藥廠 對cd3具特異性之抗體及其用途
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
US20220273568A1 (en) * 2019-07-12 2022-09-01 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of dexmedetomidine
EP4007576A4 (de) * 2019-08-01 2023-05-10 InCarda Therapeutics, Inc. Antiarrhythmische formulierung
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
EP4041308A1 (de) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulation von lymphgefässen bei neurologischen erkrankungen
EP4041312A4 (de) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Verfahren zur behandlung einer augenstörung
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
EP4093426A1 (de) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulation von lymphgefässen bei neurologischen erkrankungen
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
JP2023535604A (ja) 2020-07-30 2023-08-18 ファイザー・インク 遺伝子複製を有する細胞およびその使用
EP4203989A2 (de) 2020-09-03 2023-07-05 Rampart Bioscience, Inc. Lösliche alkalische phosphatasekonstrukte und expressionsvektoren mit einem polynukleotid zur codierung löslicher alkalischer phosphatasekonstrukte
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
JP2024517745A (ja) 2021-04-29 2024-04-23 ボストンジーン コーポレイション 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2024015561A1 (en) 2022-07-15 2024-01-18 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
CN115486539A (zh) * 2022-09-14 2022-12-20 厦门遇见今生生物科技有限公司 具有抗衰老及端粒延长的草药提取物仿生膜及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588887A5 (de) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (de) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
FI860430A0 (fi) * 1986-01-29 1986-01-29 Imatran Voima Oy Foerfarande och anordning foer utnyttjande av vaermeenergi som frigoers i kylprocess.
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
ATE141166T1 (de) * 1986-12-23 1996-08-15 Liposome Co Inc Guanidinaminoglycosid enthaltende liposome
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
IN168530B (de) * 1987-11-06 1991-04-20 Lyphomed Inc
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds

Also Published As

Publication number Publication date
GR3034954T3 (en) 2001-02-28
RO116341B1 (ro) 2001-01-30
HUT75162A (en) 1997-04-28
FI962048A0 (fi) 1996-05-14
RU2160093C2 (ru) 2000-12-10
ATE196248T1 (de) 2000-09-15
JPH09505301A (ja) 1997-05-27
FI115823B (fi) 2005-07-29
CA2176712A1 (en) 1995-05-26
IL111628A (en) 2002-08-14
NZ276305A (en) 1997-10-24
BR9408072A (pt) 1997-08-12
PL314485A1 (en) 1996-09-16
EP0729351A4 (de) 1998-02-04
BG100596A (bg) 1996-12-31
NO962024D0 (no) 1996-05-15
NO304577B1 (no) 1999-01-18
WO1995013796A1 (en) 1995-05-26
US6132766A (en) 2000-10-17
EP0729351A1 (de) 1996-09-04
FI962048A (fi) 1996-07-15
ES2149955T3 (es) 2000-11-16
DE69425901D1 (de) 2000-10-19
PT729351E (pt) 2000-12-29
DK0729351T3 (da) 2000-10-16
EP0729351B1 (de) 2000-09-13
CN1099868C (zh) 2003-01-29
HU9601316D0 (en) 1996-07-29
CA2176712C (en) 2000-05-23
JP3002702B2 (ja) 2000-01-24
KR100241300B1 (ko) 2000-03-02
AU1053595A (en) 1995-06-06
AU686277B2 (en) 1998-02-05
IL111628A0 (en) 1995-01-24
CN1140989A (zh) 1997-01-22
ZA949063B (en) 1995-09-13
NO962024L (no) 1996-07-09
DE69425901T2 (de) 2001-04-26

Similar Documents

Publication Publication Date Title
BG63146B1 (bg) Капсули с контролирано освобождаване на активнитевещества
US5422120A (en) Heterovesicular liposomes
US5723147A (en) Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5807572A (en) Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
CA2067178C (en) Solid tumor treatment method and composition
CA2078666C (en) Heterovesicular liposomes
EP0781123B1 (de) Zubereitung multivesikulärer liposomen zur gesteuerten freisetzung von wirkstoffen
EP0706374B1 (de) Verfahren zur herstellung von liposomen
CA1263310A (en) Small particle aerosol liposome and liposome-drug combinations for medical use
CA1323568C (en) Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5576017A (en) Heterovesicular liposomes
Shivhare et al. A Review on Liposomes as a Novel Drug Delivery System
NZ247547A (en) Process for preparing heterovesicular lipid vesicles or liposomes; vesicles containing a chloride and an active agent
JPH11222423A (ja) 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子